TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in Glycosylated Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Calcium intake (mg/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged Smoking Abstinence at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged Smoking Abstinence at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-Day Point Prevalence Smoking Abstinence at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-Day Point Prevalence Smoking Abstinence at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-Day Point Prevalence Smoking Abstinence at 26 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to note completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change over time in Clinician Administered PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With SDAI Remission (≤ 3.3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma and tissue cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TR grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Polyp detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: differences in CRC screening adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: differences in stage of adoption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in diabetes self management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Persistent pain: Pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of development & progression of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects Pain Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of the block for surgical anesthesia and analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom From Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in therapeutic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Performance of the LiverFASt test for NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 2 diabetes incidence
Endpoint domain: Mortality/survival
Primary endpoint: Metabolic syndrome incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subscores of Autism Diagnostic Interview (ADI-R)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30 Days MACE (death, myocardial infarction, target vessel revascularization)
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical response (prostate-specific antigen level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of perioperative antibiotic prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of perioperative antibiotic prophylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal postpartum weight retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in LLFDI Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lean Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maslach Burnout Inventory (MBI) Emotional Exhaustion (EE) Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Maslach Burnout Inventory (MBI) Depersonalization (DP) Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Maslach Burnout Inventory (MBI) Personal Achievement (PA) Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mini-Z Questionnaire (Mini-Z) Question 3
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Resident and Fellow Well-Being Index (WBI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: dyskinesia onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of anastomotic leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DMF index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic running performance evaluation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical speed in swimming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis accuracy of circRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous Dermatomyositis Disease Area and Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical symptoms of Intestinal Methane Overgrowth (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in clinical symptoms of Intestinal Methane Overgrowth (PROMIS-GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in clinical symptoms of Intestinal Methane Overgrowth (BSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: modified PASI (mPASI) score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence rates of AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of diagnosing lung nodule with ENB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bleeding on probing change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC GIR 0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum anti-rotavirus IgA antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of positive culture on patient stopcock set
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of multidrug resistant bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: Phenylephrine use
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Sensitized Patients Who Become Cross-match Compatible
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerated dose (MTD) of siltuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCLisp (0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax Lisp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchial smooth muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in Perceived Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentric muscular peak torque of the knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intimal hyperplasia area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Immunologic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood-oxygen-level-dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Pain-Free Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-Rated Tennis Elbow Evaluation (PRTEE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Event-free survival to first detected AF
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in NCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in Von frey filament test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in the geometric mean titers of HI post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokines and MMP's levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Length of Time Participants Can Hold a Hand-grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow Mediated Dilation (FMD) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean symptom score (MSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Fatigue Symptom Inventory (FSI)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Affect Balance Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient rate with complete healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: range of cerebral autoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy for variceal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Competitive Employment-Total Jobs
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Competitive Employment-Participants With Competitive Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Competitive Employment-Percentage of Participants With Competitive Employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain assessment using FLACC or FPS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Employment-related Social Skills Knowledge as Assessed by Test of Employment Social Skills (TESS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Employment-related Social Skills Knowledge as Assessed by Adapted Contextual Assessment of Social Skills (CASS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Social Skills Knowledge as Assessed by Social Responsiveness Scale (SRS-2)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pain numerical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kolcaba comfort scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lower Extremity Electromyography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of Submental Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial Subgingival Biofilm Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Resolution of Influenza-related Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of physical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Quality of Life related to TMD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Retention on the Postural Stepping Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Relapse
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Circadian rhythm of rest-activity post anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response (Partial Response or Complete Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: inflammatory profile of epicardial adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Children's Yale-Brown Obsessive Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parental satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Infant lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest CT scan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to major coronary event
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to prophylaxis programme
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Efficacy of misoprostol administration routes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Accuracy of PET-CT for lung tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of PET-CT for thoracic adenopathy detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to Moderate Vision Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geographic Atrophy (GA) Growth Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Hormone deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dienogest use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of catheter-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: MRD Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best objective intracranial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stabilization of haemodynamic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived behavioral control (self-efficacy)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vascular changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants with RVNA titer ≥ 0.5 IU/mL at Day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Persistence at 6 months and 12 months after the first vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Pulmonary Embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of days participants walked recommended steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Core Outcome Measure Index (COMI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 17-Item Hamilton Depression Rating Scale (HAM-D17) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Any Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Adverse Events (AEs) ≥ grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Latent Tuberculosis Infection (LTBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Obsessive compulsive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in patients' symptom questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of IOL calculations vs. aberrometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days per week with headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newly developed gastric neoplasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in PTSD Checklist (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Social Adjustment Scale-Self Report (SAS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in IgG trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-time curve From 0-t of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-time curve From 0 to infinity of Fluzoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of neratinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OMI-20 Total Score Change From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of moderate/severe hypoxemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of treatment fractions delivered successfully
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from study-related major adverse cardiovascular and neurological events (MACNE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Relative Risk of Heart Failure Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of procedural sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of procedural sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of transition to ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first occurrence of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with specific diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Systemic toxicity according to NCI Common Toxicity Criteria version 2
Endpoint domain: Adverse events/effects
Primary endpoint: PDT-related normal tissue toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Combined rate of moderate and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain measured with the visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Antidrug Antibodies (ADA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability measured by grade 3 and 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Achievement of normal values in the chair-rising test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reduction post CS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Myasthenia Gravis (MG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessment of motor activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bishop Score of 6 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes